BackRegeneron Pharmaceuticals Overview
Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Target Price

See Regeneron Pharmaceuticals's analyst price targets ($820) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$784.36

Average Target Price

$815.654% upside

26 analysts in the last 4 months

High: $1030 | Low: $641

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-03Guggenheim$1,03031.3% upsideOpen
2026-07-31Wells Fargo$7504.4% downsideOpen
2026-07-31RBC Capital$7376% downsideOpen
2026-07-31Robert W. Baird$7613% downsideOpen
2026-07-31Cantor FitzgeraldCarter Gould$7951.4% upsideOpen
2026-07-31Morgan Stanley$7583.4% downsideOpen
2026-07-21GuggenheimYatin Suneja$1,00027.5% upsideOpen
2026-07-09Piper SandlerBiren Amin$8548.9% upsideOpen
2026-07-08Morgan StanleyTerence Flynn$7306.9% downsideOpen
2026-07-07Truist Financial$7692% downsideOpen
2026-07-06HSBC$8002% upsideOpen
2026-07-06Cantor Fitzgerald$7504.4% downsideOpen
2026-05-19Canaccord GenuityJohn Newman$87511.6% upsideOpen
2026-05-18Evercore ISI$8255.2% upsideOpen
2026-05-18RBC Capital$7079.9% downsideOpen
2026-05-18Wolfe ResearchAlexandria Hammond$8609.6% upsideOpen
2026-05-18Leerink PartnersMarket Perform$64118.3% downsideOpen
2026-05-18BMO Capital$7306.9% downsideOpen
2026-05-18Piper Sandler$8559% upsideOpen
2026-05-18Truist Financial$7780.8% downsideOpen
2026-05-01GuggenheimYatin Suneja$99526.9% upsideOpen
2026-04-30Morgan StanleyTerence Flynn$7880.5% upsideOpen
2026-04-30Barclays$91716.9% upsideOpen
2026-04-30Truist Financial$7961.5% upsideOpen
2026-04-22Raymond JamesChris Raymond$91016% upsideOpen
2026-04-10Morgan Stanley$7961.5% upsideOpen
2026-04-08Bernstein$92117.4% upsideOpen
2026-03-09Truist FinancialGreg Renza$8184.3% upsideOpen
2026-03-06BarclaysEliana Merle$92317.7% upsideOpen
2026-03-02RBC CapitalBrian Abrahams$7652.5% downsideOpen
2026-02-09Guggenheim$97524.3% upsideOpen
2026-02-02Cantor FitzgeraldCarter Gould$8002% upsideOpen
2026-02-02Oppenheimer$86510.3% upsideOpen
2026-02-02Robert W. BairdBrian Skorney$7425.4% downsideOpen
2026-02-02Tudor PickeringWilliam Pickering$92517.9% upsideOpen
2026-02-01Morgan StanleyTerence Flynn$7692% downsideOpen
2026-01-30Raymond James$87010.9% upsideOpen
2026-01-27RBC CapitalBrian Abrahams$7455% downsideOpen
2026-01-27Tudor PickeringWilliam Pickering$91616.8% upsideOpen
2026-01-27Bernstein$91616.8% upsideOpen
2026-01-22Evercore ISI$87511.6% upsideOpen
2026-01-08Goldman Sachs$91416.5% upsideOpen
2025-12-17Leerink PartnersAndrew Berens$87311.3% upsideOpen
2025-12-12Morgan StanleyTerence Flynn$7682.1% downsideOpen
2025-12-10HSBC$98525.6% upsideOpen
2025-12-04BMO CapitalEvan Seigerman$8508.4% upsideOpen
2025-12-04Canaccord Genuity$1,05734.8% upsideOpen
2025-11-24HSBC$89013.5% upsideOpen
2025-11-24Scotiabank$7701.8% downsideOpen
2025-11-24Truist Financial$7981.7% upsideOpen

Regeneron Pharmaceuticals (REGN) FAQ

Regeneron Pharmaceuticals's target price stands at $820. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $820 for REGN implies 4.0% upside versus today's price ($784.36). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Regeneron Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places REGN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Regeneron Pharmaceuticals's reading of $820 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.